Intellipharmaceutics International Stock Debt To Equity
Intellipharmaceutics International fundamentals help investors to digest information that contributes to Intellipharmaceutics' financial success or failures. It also enables traders to predict the movement of Intellipharmaceutics OTC Stock. The fundamental analysis module provides a way to measure Intellipharmaceutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Intellipharmaceutics otc stock.
Intellipharmaceutics |
Intellipharmaceutics International OTC Stock Debt To Equity Analysis
Intellipharmaceutics' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Intellipharmaceutics Debt To Equity | 165.20 % |
Most of Intellipharmaceutics' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Intellipharmaceutics International is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
CompetitionAccording to the company disclosure, Intellipharmaceutics International has a Debt To Equity of 165%. This is 208.55% higher than that of the Pharmaceuticals sector and notably higher than that of the Health Care industry. The debt to equity for all United States stocks is notably lower than that of the firm.
Intellipharmaceutics Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Intellipharmaceutics' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Intellipharmaceutics could also be used in its relative valuation, which is a method of valuing Intellipharmaceutics by comparing valuation metrics of similar companies.Intellipharmaceutics is currently under evaluation in debt to equity category among its peers.
Intellipharmaceutics Fundamentals
| Return On Asset | -0.98 | ||||
| Operating Margin | (106.06) % | ||||
| Current Valuation | 4.47 M | ||||
| Shares Outstanding | 33.09 M | ||||
| Shares Owned By Insiders | 1.70 % | ||||
| Shares Owned By Institutions | 11.09 % | ||||
| Number Of Shares Shorted | 714 K | ||||
| Price To Earning | (0.50) X | ||||
| Price To Sales | 66.19 X | ||||
| Gross Profit | 1.4 M | ||||
| EBITDA | (4.45 M) | ||||
| Net Income | (5.15 M) | ||||
| Cash And Equivalents | 79.65 K | ||||
| Total Debt | 2.01 M | ||||
| Debt To Equity | 165.20 % | ||||
| Current Ratio | 0.05 X | ||||
| Book Value Per Share | (0.31) X | ||||
| Cash Flow From Operations | (2.46 M) | ||||
| Short Ratio | 0.39 X | ||||
| Earnings Per Share | (0.16) X | ||||
| Target Price | 25.0 | ||||
| Number Of Employees | 11 | ||||
| Beta | 1.0 | ||||
| Market Capitalization | 2.02 M | ||||
| Total Asset | 2.1 M | ||||
| Retained Earnings | (86.55 M) | ||||
| Working Capital | (5.62 M) | ||||
| Current Asset | 1.41 M | ||||
| Current Liabilities | 7.02 M | ||||
| Z Score | -65.8 | ||||
| Net Asset | 2.1 M |
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Other Consideration for investing in Intellipharmaceutics OTC Stock
If you are still planning to invest in Intellipharmaceutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intellipharmaceutics' history and understand the potential risks before investing.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Global Correlations Find global opportunities by holding instruments from different markets |